Compare OKYO & PGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OKYO | PGZ |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 66.6M |
| IPO Year | 2021 | N/A |
| Metric | OKYO | PGZ |
|---|---|---|
| Price | $1.09 | $8.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 282.3K | 22.3K |
| Earning Date | 07-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.26% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $8.62 |
| 52 Week High | $3.20 | $10.58 |
| Indicator | OKYO | PGZ |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 33.97 |
| Support Level | N/A | N/A |
| Resistance Level | $1.70 | $9.16 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 20.23 | 2.83 |
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.